{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:05:54Z","timestamp":1793325954154,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.annonc.2020.08.2102","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T20:44:29Z","timestamp":1601325869000},"page":"1606-1622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":463,"title":["ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"R.E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bowtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Garsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nik-Zainal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.08.2102_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dnarep.2014.01.009","article-title":"Non-homologous end joining: emerging themes and unanswered questions","volume":"17","author":"Radhakrishnan","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.annonc.2020.08.2102_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib6","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib10","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib14","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.08.2102_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.08.2102_bib16","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib17","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.annonc.2020.08.2102_bib18","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.08.2102_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group","volume":"11","author":"Teutsch","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","article-title":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","volume":"25","author":"McAlpine","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/sj.onc.1203463","article-title":"Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers","volume":"19","author":"Dion","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2020.08.2102_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00004347-200004000-00009","article-title":"Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation","volume":"19","author":"Garcia","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib24","series-title":"WHO Classification of Tumors of the Female Reproductive Organs","author":"Kurman","year":"2014"},{"key":"10.1016\/j.annonc.2020.08.2102_bib25","series-title":"WHO Classification of Tumors of the Female Reproductive Organs","year":"2020"},{"key":"10.1016\/j.annonc.2020.08.2102_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"Kobel","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib27","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/arpa.2019-0009-SA","article-title":"Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine","volume":"143","author":"Compton","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-012-1356-2","article-title":"KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance","volume":"462","author":"Dijkstra","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.annonc.2020.08.2102_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.annonc.2020.08.2102_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib33","doi-asserted-by":"crossref","first-page":"43653","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","volume":"8","author":"Dougherty","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2020.08.2102_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib39","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib41","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2102_bib42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.08.2102_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/jmg.2007.056895","article-title":"Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex\u00a0vivo assay based on a splicing reporter minigene","volume":"45","author":"Bonnet","year":"2008","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrg775","article-title":"Listening to silence and understanding nonsense: exonic mutations that affect splicing","volume":"3","author":"Cartegni","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41436-019-0729-1","article-title":"Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort","volume":"22","author":"Li","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib46","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1158\/0008-5472.CAN-20-0895","article-title":"Calibration of pathogenicity due to variant-induced leaky splicing defects by using BRCA2 exon 3 as a model system","volume":"80","author":"Tubeuf","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41525-018-0046-7","article-title":"Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices","volume":"3","author":"Toland","year":"2018","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib49","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","article-title":"BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance","volume":"26","author":"Eccles","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","article-title":"BRCA1 promoter methylation predicts adverse ovarian cancer prognosis","volume":"101","author":"Chiang","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib51","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4161\/epi.22561","article-title":"BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer","volume":"7","author":"Stefansson","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.annonc.2020.08.2102_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ygyno.2017.12.004","article-title":"Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma","volume":"148","author":"Bernards","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib53","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2020.08.2102_bib54","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","article-title":"BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients\u2013a study of the tumour bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)","volume":"50","author":"Ruscito","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2102_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.08.2102_bib56","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-13-0066","article-title":"Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations","volume":"19","author":"George","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib57","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib58","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A\u00a0mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1476-4598-8-48","article-title":"Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas","volume":"8","author":"Swisher","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2020.08.2102_bib60","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib61","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.08.2102_bib62","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib63","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2102_bib64","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.08.2102_bib65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib66","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib67","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.08.2102_bib69","doi-asserted-by":"crossref","first-page":"e1006799","DOI":"10.1371\/journal.pcbi.1006799","article-title":"Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models","volume":"15","author":"Funnell","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"10.1016\/j.annonc.2020.08.2102_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/djx176","article-title":"Genomic rearrangement signatures and clinical outcomes in high-grade serous ovarian cancer","volume":"110","author":"Hillman","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.08.2102_bib71","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib72","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib73","doi-asserted-by":"crossref","first-page":"e113169","DOI":"10.1371\/journal.pone.0113169","article-title":"A\u00a0genomic instability score in discriminating nonequivalent outcomes of BRCA1\/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2020.08.2102_bib74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.08.2102_bib75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib76","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","article-title":"Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib77","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","article-title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","volume":"25","author":"Staaf","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib78","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/gim.2017.241","article-title":"Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project","volume":"20","author":"Robbe","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib79","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/0008-5472.CAN-12-0324","article-title":"Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival","volume":"72","author":"Mukhopadhyay","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib80","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.08.2102_bib81","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A\u00a0marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib82","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-18-0063","article-title":"Functional ex\u00a0vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects","volume":"24","author":"Meijer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.08.2102_bib83","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2020.08.2102_bib84","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A\u00a0RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.annonc.2020.08.2102_bib85","unstructured":"FDA USA 2020. FDA approves niraparib for first-line maintenance of advanced ovarian cancer. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer. Accessed May 8, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib86","unstructured":"FDA USA 2020. FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary. Accessed May 18, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib87","unstructured":"EMA 2018. EMA approval of olaparib. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003726\/human_med_001831.jsp&mid=WC0b01ac058001d124. Accessed September 12, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib88","unstructured":"FDA USA 2017. FDA approval of olaparib. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer. Accessed September 12, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib89","unstructured":"EMA 2017. EMA approval of niraparib. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zejula. Accessed September 12, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib90","unstructured":"EMA2018. EMA approval of rucaparib. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/rubraca. Accessed February 15, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib91","unstructured":"FDA USA 2017. FDA approval of niraparib. Available at: www.fda.gov\/drugs\/resources-information-approved-drugs\/niraparib-zejula. Accessed February 15, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib92","unstructured":"FDA USA 2018. FDA approval of rucaparib. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal. Accessed February 15, 2020."},{"key":"10.1016\/j.annonc.2020.08.2102_bib93","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.08.2102_bib94","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.08.2102_bib95","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP inhibitors: extending benefit\u00a0beyond BRCA-mutant cancers","volume":"25","author":"Pilie","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420421647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420421647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:59:40Z","timestamp":1760335180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420421647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":95,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0923753420421647"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2102","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}